Similarly, GNE-781 exhibited highly potent and selective CBP/p300 inhibitory activity in a MOLM-16 AML xenograft model, demonstrating good in vivo pharmacokinetics, no central nervous system (CNS) penetration, and a dose-dependent decrease in Foxp3 transcript levels [90]. The gene discussed is CREBBP; the disease is acute myeloid leukemia.